Introduction
Glioblastoma multiforme (GBM), the highest grade (IV) of malignant gliomas, is relatively rare, occurring at a rate of seven per 100 000 tumors, yet is common among brain tumors. GBM can progress from lower grade astrocytic gliomas or arise de novo. Regardless of origin, grade IV GBM is associated with an extremely poor prognosis [1, 2] . Even after optimal treatment with function-saving surgical resection followed by both radiation and chemotherapy, the median survival of patients newly diagnosed with GBM is slightly more than a year [3] . Trials investigating new therapies for GBM generally involve relapsed or progressive patients. A summary of eight phase II trials with cytotoxic or cytostatic drugs for treatment of recurrent GBM at a single center resulted in a 6-month progression-free survival rate of 15% and a median overall survival rate of 30 weeks [4] . Together, these observations suggest that the vast majority of glioblastoma patients will experience fatal disease progression within the first 2 years.
Preclinical investigations have focused on gaining insight into the molecular basis for glioblastoma oncogenesis with the aim of identifying potential therapeutic targets. There is considerable support for the hypothesis that platelet-derived growth factor (PDGF) autocrine signaling plays a role in the transformation of gliomas [5] [6] [7] [8] [9] [10] [11] [12] . This has prompted the notion that inhibition of PDGF receptors (PDGFRs) might directly arrest GBM by interrupting an autocrine growth cycle [13, 14] . Alternatively, inhibition of PDGFRs may affect GBM tumor growth by indirect mechanisms relating to the tumor stroma or vasculature [15] [16] [17] .
Imatinib is a small molecule inhibitor of PDGFRa and b, as well as KIT, ABL, BCR-ABL and ARG tyrosine kinases [18, 19] . Imatinib is indicated for treatment of chronic myelogenous leukemia [20] [21] [22] [23] and unresectable or metastatic gastrointestinal stromal tumor (GIST) [24] [25] [26] .
Preliminary trials with imatinib as monotherapy for treatment of GBM have been conducted [27] . A multi-center phase II study of imatinib in 51 patients with recurrent GBM, obtained confirmed partial responses in two patients treated with imatinib 600 mg and in one patient treated with imatinib 800 mg for longer than 10 months. Prolonged tumor stabilizations for longer than 6 months were reported in one patient taking imatinib 600 mg and in four patients taking imatinib 800 mg. An earlier phase I trial examined 40 patients with malignant primary brain tumors, including 24 with GBM, treated with imatinib [28] . Among 31 evaluable patients, 14 maintained stable disease and of those, four maintained stability for as long as 24 weeks.
The reasons underlying this level of efficacy with imatinib monotherapy for treatment of GBM are not clearly understood. Interestingly, a recent phase II trial investigating the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, as monotherapy for recurrent GBM, yielded modest results in a subpopulation of patients [29] . Together, results from these trials with targeted kinase inhibitors for recurrent/relapsed GBM patients suggest that perhaps such agents may be expected to exhibit efficacy as monotherapy in only subsets of patients. Whether related to tumor complexity or variability, these results raise the possibility that a combinatorial approach may be more beneficial.
Preclinical studies provide evidence that imatinib increases the chemo-or radiosensitivity of glioblastoma cells as well as of soft tissue sarcomas and leukemic cells in culture [30] [31] [32] [33] [34] , suggesting that imatinib may enhance the activity of chemotherapeutic agents used to treat GBM. Hydroxyurea, a cytotoxic agent that inhibits DNA synthesis, is widely used in cancer therapy and penetrates the blood-brain barrier [35, 36] . This patient series investigated the combination of imatinib and hydroxyurea in patients with progressive temozolomide-resistant GBM.
Patients and methods
Thirty GBM patients with disease progression, refractory to radiation therapy and chemotherapy (temozolomide plus nitrosourea), and with no other treatment option available to them, were included in this series ( Figure 1 , Table 1 ). Only patients with World Health Organization (WHO) tumor classification grade IV tumors diagnosed by two different independent neuropathologists participated. Disease progression, according to Southwestern Oncology Group (SWOG) criteria, was documented by two magnetic resonance imaging (MRI) scans within 6 weeks and 3 months.
The median age of patients was 44 years ( Table 2 ). All 30 patients had radiation therapy between 50 and 60 Gy following surgical resection ( Figure  1 , Table 1 ). Patients in the series then had at least two chemotherapy cycles with temozolomide plus nitrosourea, except one patient who had three. It was mandatory that surgical and radiation options were excluded by a neurosurgeon and radiotherapist before inclusion in this series. One patient experienced a rapid progression during irradiation combined with temozolomide chemotherapy, which was documented by MRI scan 4 weeks after the start of treatment. Systemic treatment was changed to nimustine hydrochloride (ACNU) with continued radiotherapy. Following significant progression, this patient entered the investigational series less than 3 months from the time of confirmed diagnosis. Twenty-eight patients had a second progression of GBM and one patient was experiencing a third progression of GBM upon entering the study. All patients received dexamethasone in a median dose of 12 mg/day (range 8-24 mg/day). Immunohistochemical examinations could not be performed in the majority of cases. Co-morbidities of patients participating in this series are listed in Table 3 . Patients with co-morbid hypertension were all well treated for the condition and the comorbid condition of diabetes was not attributed to steroid induction in any patient. Twenty-six patients received enzyme-inducing anticonvulsants, four patients received non-enzyme-inducing anticonvulsants, and three patients were exposed to both (Table 3) . Eastern Cooperative Oncology Group (ECOG) performance status at the start of therapy was 0, 1 or 2.
Treatment costs were paid by the patient or by a clinic fund, and in eight cases by insurance after efficacy was indicated. Patient consent for participation was confirmed by a third person in each case (Table 1 ). Figure 1 . Diagram of treatment regimen for patients in this series prior to initiation of imatinib plus hydroxyurea therapy. The point at which Patient 27, with rapidly progressing disease, entered the investigational series after failing radiation plus temozolomide and ACNU therapy less than 3 months from confirmed diagnosis is indicated by *. Patients were treated with imatinib 400 mg once daily and hydroxyurea 500 mg twice daily and were monitored by clinical examination, weekly blood cell counts, and MRI every 6 weeks for as long as patients remained clinically stable on treatment. SWOG criteria were used for evaluation of objective tumor response to treatment. All scans were evaluated by a radiologist and reviewed by the investigator. Scans were subsequently blinded for independent radiological evaluation by Gregory Sorensen (Massachusetts General Hospital, Charlestown, MA, USA). Clinical benefit was defined to include both partial and complete responses as well as stable disease lasting at least 3 months. Patients with tumor growth, detected by MRI, that did not satisfy SWOG criteria of progressive disease and did not lead to a decrease in performance status (no increased steroid dose required) were treated with imatinib 600 mg/day with no change in hydroxurea dose.
Results
Thirty patients were evaluable for safety and efficacy after a median observation time of 19 weeks (range 4-148 weeks) ( Table 4) . One patient reached complete response lasting 12 months and five patients reached a partial response in MRI scan lasting a median of 3 months (range 6 weeks to 25 months). A series of MRI scans from Patients 11 and 14, listed in Table 4 , illustrates the extent of responses to imatinib plus hydroxyurea from baseline (documented progression) throughout several months of therapy. Patient 14 achieved a partial response and Patient 11 reached stable disease (Figure 2) . The response rate, including partial and complete responses, was 20% (Table 5) . Eleven patients reached stable disease for a median of 6 months (range 3-32 months). With regard to the inclusion criteria and the expected outcome of these patients, clinical benefit was defined as disease stabilization for a minimum of 3 months or more. Patients with stable disease, combined with responding patients, yielded a clinical benefit rate of 57%. Thirteen patients progressed without response or stable disease. Patient 11 progressed after a 142-week period of stable disease and died 6 weeks later and Patient 16 progressed after a 108-week period of stable disease and is still alive 8 weeks later, having another stable disease period 6 weeks after treatment start with liposomal pegylated doxorubicin. Two other patients remain alive without progression for 122 and 106 weeks, respectively. Among these patients, Patient 14 had a partial response lasting 12 weeks and then maintained stable disease and Patient 22 had a durable stable disease. Patient 4 maintained stable disease for 104 weeks before progressing to death. Twenty-five patients finally died with progressive disease. The median time to progression for all 30 patients was 10 weeks. Six-month and 2-year progression-free survival rates for all patients in the series were 32% and 16%, respectively ( Figure 3A) . Median overall survival was 19 weeks and the shortest and longest survival durations were 4 and 148 weeks, respectively ( Figure 3B ).
There was no treatment interruption and there were no grade 3 or 4 toxicities. Four patients experienced grade 2 edema and six patients experienced grade 2 abdominal pain. One patient had grade 2 neutropenia (Table 6 ). Two patients died of pulmonary embolism, one patient having a partial response according to MRI scan and one patient with stable disease. Both events are considered unrelated to treatment with imatinib and hydroxyurea since thrombosis and thrombo-embolic complications are frequent occurrences in progressive glioblastoma [37] [38] [39] .
Discussion
The current standard for newly diagnosed GBM, when feasible, is surgical resection followed by radiotherapy and, more recently, by chemotherapy. In a recent phase II trial, 573 newly diagnosed GBM patients were randomized to receive radiotherapy or radiotherapy plus concomitant or adjuvant temozolomide, a recently available alkylating agent with antitumoral efficacy in GBM [40] . Eighty-four per cent of patients in this trial had had previous surgical resection. The combination of temozolomide and radiotherapy resulted in a 2-year survival rate of 26% compared with 10% for radiotherapy alone. Median overall survival was 15 months for patients treated with the combination and 12 months for patients treated with radiotherapy alone. Trials investigating new therapies for GBM generally involve relapsed or progressive patients. Temozolomide was tested in two separate trials involving hundreds of GBM patients at first relapse, with or without prior chemotherapy [41, 42] . Six-month progression-free survival rates of 18% and 21% were obtained. This investigational series of treatment-refractory GBM patients treated with imatinib plus hydroxyurea yielded a clinical benefit rate, defined as either tumor response (partial or complete response) or as stable disease lasting at least 3 months, in 57% of patients. Among 30 patients, five patients achieved partial and one patient achieved complete response that lasted approximately 3 months for a total response rate of 20%. The 6-month progression-free survival rate was 32% and the 2-year progression-free survival rate was 16%. These results are comparable with published studies in investigational trials with recurrent or relapsed GBM patients [1, 4, 41, 42] .
Combination therapy with these two agents was well tolerated with no grade 3 or 4 toxicities. Two patients died of pulmonary embolism, a well-known complication with progressive GBM Imatinib 600 mg/day. NS, not stated because death not related to tumor; PD, progressive disease; PE, pulmonary embolism; CR, complete remission; PR, partial response; SD, stable disease. [37] [38] [39] . A relationship between pulmonary embolism and treatment was considered unlikely. Because the patients in this study were relatively young (median 44 years) and with good initial performance status, it is likely that the proportion of secondary GBM was higher in this population compared with a more elderly population [43] . Nevertheless, previous studies have observed no difference in the prognostic significance between primary and secondary grade IV GBM among age-matched patients. This suggests that the prognosis among patients in this series was likely to be similar [44] . Moreover, while one of the youngest patients attained disease control for a period, the other never responded and neither patient is among the longest-lived subset. It is possible that a subset of patients in this series may have been predisposed to respond to PDGFR inhibition and that this sensitivity was contingent on whether the GBM was primary or transformed [5] [6] [7] [8] [9] [10] [11] [12] 43] . Future studies may resolve this issue.
Several possible explanations could underlie the positive results obtained with the combination of hydroxyurea and imatinib compared with single-agent imatinib. Although the extent to which imatinib penetrates the blood-brain barrier in GBM is unknown, hydroxyurea, by virtue of its ability to traverse the blood-brain barrier, may enhance the crossing of imatinib by inhibiting activity of ABCG2 ATP or P-glycoprotein, multidrug transporters with affinity for imatinib [45, 46] . Imatinib also inhibits ABCG2 activity, indicating the potential for a complex cumulative interaction of hydroxyurea and imatinib that elevates and prolongs central nervous system concentrations of both agents. During combination therapy imatinib may reach target cells somehow differently than in the single-agent setting, possibly by an adjuvant-type interaction [47] .
It should also be noted that the majority of patients in this series were treated with enzyme-inducing anticonvulsants. The effect of these agents on the pharmacokinetics and pharmacodynamics of imatinib plus hydroxyurea in GBM patients is presently unknown but is a factor to consider with respect to the mechanism of action of this combination.
In the brain, imatinib may engage its potential array of antitumor mechanisms that may include direct or indirect effects on tumor growth through inhibition of PDGFRs. PDGFR signaling has been demonstrated to directly promote glioblastoma cell survival and growth in culture as well as in living mice [8] [9] [10] [11] , whereas inhibition of PDGFR signaling suppresses cell growth [7, 14] . The hypothesis that aberrant PDGFR signaling may be involved in glioblastoma transformation is consistent with observations that human glial tumors overexpress PDGFRs compared with normal brain tissue [6, 48] .
In addition to the direct role that PDGFR signaling may play in the proliferation of brain tumor cells, there is also the possibility that indirect mechanisms of PDGFR signaling contribute to brain tumor growth. Inhibition of PDGFRs expressed on pericytes associated with blood vessel endothelial cells might suppress brain tumor growth via an anti-angiogenic mechanism [49] . Furthermore, expression of PDGF and PDGFRs on tumor 2-year progression-free survival rate 16%
Median time to progression 10 weeks stromal cells can also affect tumor growth by regulating interstitial fluid pressure or other tissue factors that influence uptake of drugs into tumors [50] . Another possible mechanism of action of imatinib, which is likely to be independent of PDGFRs, is suggested by evidence that in isolated cells in culture, imatinib sensitizes transformed cells to the cytotoxic effects of chemotherapeutic agents that interfere with DNA metabolism, or more recently reported, to radiotherapy [30, 33, 34] . In this series of patients, cytotoxicity would not be expected to play a major role in defeating GBM because all patients were refractory to nitrosourea. However, combination therapy with imatinib may have potentiated the chemosensitivity of tumor cells [31, 32, 34] .
While the precise mechanisms and interactions relevant to imatinib efficacy in this series of patients are not clear, the observations indicate that the combination of hydroxyurea and imatinib shows promise as a safe and effective therapy for a subpopulation of otherwise treatment refractory GBM patients. This is accomplished either through the induction of response or disease control with concomitant long-term survival in this subset of patients. Trials are underway to evaluate further this combination as treatment of GBM, as well as to characterize better the subpopulation of responding patients to perhaps select for those most likely to benefit from the combination in the future. 
